Member Info for draft

Here, get in

https://londonsharetips.wordpress.com/

Kirkstall 28% stake Sales of its ‘organ-on-a-chip` system, Quasi Vivo™, are ahead of forecast Competitor recently sold for £50 million, Cyprotex was aim listed. Global `organ-on-a-chip` market is poised to grow at a compound annual growth rate of around 69% over the next decade to reach approximately $6.13 billion by 2025. In the quarter ended 30 September 2016, sales of Quasi VivoTM exceeded management forecasts, particularly in the USA, where Kirkstall is represented by Triangular Research Labs (part of Lonza Group, one of the world’s leading suppliers to the Pharma & Biotech and Specialty Ingredient markets). Paraytec 33% stake Sales have now begun of Paraytec’s recently introduced its ActiPix™ D200 system into the global pharmaceutical market. The partner distributing Actipix, Malvern Instruments has just merged with X-ray technology specialist PANalytical, which is headquartered in The Netherlands. Both companies are owned by parent company Spectris plc and are operating companies within the materials analysis segment of Spectris. Paraytec’s instruments can also be used to monitor how tablets, gels and creams, release their active ingredients into liquids, including biological media, as well as across membranes such as skin. Gyrometric 47% stake Patent protected system of hardware and software to monitor the vibrations in rotating shafts. Established sales partners in Germany and Asia on which it will now build and expects to be breakeven in 2017.

Kirkstall 28% stake Sales of its ‘organ-on-a-chip` system, Quasi Vivo™, are ahead of forecast Competitor recently sold for £50 million, Cyprotex was aim listed. Global `organ-on-a-chip` market is poised to grow at a compound annual growth rate of around 69% over the next decade to reach approximately $6.13 billion by 2025. In the quarter ended 30 September 2016, sales of Quasi VivoTM exceeded management forecasts, particularly in the USA, where Kirkstall is represented by Triangular Research Labs (part of Lonza Group, one of the world’s leading suppliers to the Pharma & Biotech and Specialty Ingredient markets). Paraytec 33% stake Sales have now begun of Paraytec’s recently introduced its ActiPix™ D200 system into the global pharmaceutical market. The partner distributing Actipix, Malvern Instruments has just merged with X-ray technology specialist PANalytical, which is headquartered in The Netherlands. Both companies are owned by parent company Spectris plc and are operating companies within the materials analysis segment of Spectris. Paraytec’s instruments can also be used to monitor how tablets, gels and creams, release their active ingredients into liquids, including biological media, as well as across membranes such as skin. Gyrometric 47% stake Patent protected system of hardware and software to monitor the vibrations in rotating shafts. Established sales partners in Germany and Asia on which it will now build and expects to be breakeven in 2017.

Plenty of time to get in

Good rewards coming here for the patient

Of where we currently are

Just got to stay positive here

Can someone quickly give me a summary of the Derampers are here, I'll filter them.

Well placed to take advantage of animal testing ban https://www.plantbasednews.org/post/animal-tested-cosmetics-banned-in-switzerland

I think something being hidden though

http://www.proactiveinvestors.co.uk/companies/news/171333/braveheart-investment-keeping-the-momentum-going-171333.html Expect fireworks, transformed company with solid investments

Has a 20% shareholding here

Kirkstall 28% stake Sales of its ‘organ-on-a-chip` system, Quasi Vivo™, are ahead of forecast Competitor recently sold for $50million Global `organ-on-a-chip` market is poised to grow at a compound annual growth rate of around 69% over the next decade to reach approximately $6.13 billion by 2025. In the quarter ended 30 September 2016, sales of Quasi VivoTM exceeded management forecasts, particularly in the USA, where Kirkstall is represented by Triangular Research Labs (part of Lonza Group, one of the world’s leading suppliers to the Pharma & Biotech and Specialty Ingredient markets). Paraytec 33% stake Sales have now begun of Paraytec’s recently introduced its ActiPix™ D200 system into the global pharmaceutical market. The partner distributing Actipix, Malvern Instruments has just merged with X-ray technology specialist PANalytical, which is headquartered in The Netherlands. Both companies are owned by parent company Spectris plc and are operating companies within the materials analysis segment of Spectris. Paraytec’s instruments can also be used to monitor how tablets, gels and creams, release their active ingredients into liquids, including biological media, as well as across membranes such as skin. Gyrometric 47% stake Patent protected system of hardware and software to monitor the vibrations in rotating shafts. Established sales partners in Germany and Asia on which it will now build and expects to be breakeven in 2017.

Think this is going to have a big run

This guy picked up tji tejoori 40 bagger, he's taken some of this It is a tiny (£2.1m) investment trust. It has $1.4m (£1.1m) in cash (30/6/2016 HY report) – this doesnt screen well as it is held via a subsidiary…. The rest is a 24% stake in Stopharm and a 16.35% stake held via a convertible bridge loan. This is valued at $6m (£4.8m) in the books based on an indicative offer. In total this gives an upside of over 150%. IF we get to NAV. Stolfarm is a Khazakhstan pharmacy plausibly forecast to make $1.9m in 2016 – so the total valuation of Stopharm gives a PE of about 8. Kazakhstan’s economy and exchange rate has been erratic – going from 185 per USD to 335! Apparently the economy has stabilised. Costs are $500-600k per year. This gives probably about 3 years to sell Stopharm until the company is in trouble… The offer which hasn’t actually materialised is from an insider – Capital Gate holding – originally announced 29th Sep 2014 – subject to monopolies approval. On 30 June 2016 there was another expression of interest. They are continuing to try and sell the stake. The company also potentially has value as a cash shell / vehicle for something else. Upside case is there is an offer for Stolpharm and the company distributes the money to shareholders and winds itself up – ideally at a large profit. Downside is the asset is stolen in some way or the company delists and its a slow journey to getting the money back. Shareholders are reasonably dispersed – largest is Richard Horlick – former director / founder.

https://www.humanrelevantscience.org/launch-event

Why choose CN Bio? Backed by a $26M US Federal contract to develop a Human body-on-a-chip and building on technologies developed at the Massachusetts Institute of Technology, CN Bio is one of the pre-eminent Organ-on-Chip firms in this emerging field.

Bought out for £50million http://www.cyprotex.com/ Kirkstall presenting with Cyprotex early Feb

Exactly, and I'm wondering if it's a placing